Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai Inc.

WOODCLIFF LAKE, N.J., April 6, 2016 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Paul Hawthorne to the position of Senior Vice President, U.S. Commercial, Neurology Business Group. In this role, Mr. Hawthorne will be responsible for leading the U.S. Neurology Sales and Marketing teams in bringing Eisai's neurology portfolio of products to patients.

Paul Hawthorne

Mr. Hawthorne brings to Eisai significant expertise in transformational leadership, building and leading high performance teams, new product launches, P&L management, and lifecycle management.

"With his proven record for driving organizational and brand growth, we are excited to have Paul on our team," said Ivan Cheung, Chairman and CEO of Eisai Inc. and President of the Neurology Business Group. "We look forward to his contributions to our commercial organization to maximize our neurology brands, and help in ensuring that the appropriate patients have access to our products."

Mr. Hawthorne joins Eisai from Sanofi, where he spent the last 24 years in positions of increasing responsibility across all commercial functions and multiple therapeutic areas. Most recently, he held the position of Vice President (VP) of Sales, in which he was responsible for leading retail, hospital and long-term care sales forces through three product launches in the last 18 months. Prior roles include serving as VP & Head of Go To Market Center of Excellence and as VP & Head of the Oncology Business Unit.

Mr. Hawthorne holds a Master of Business Administration in Marketing from LaSalle University. He earned his Bachelor of Arts degree in Communications from the University of Pittsburgh.

Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and neurology. To learn more about Eisai Inc., please visit us at

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey and Pennsylvania, as well as a global demand chain organization that includes facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

Eisai Co. Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology. For more information about Eisai Co., Ltd., please visit

Media Inquiries

Investor Inquiries              

Patti Councill

Alex Scott

Eisai Inc.

Eisai Inc.



Photo -

SOURCE Eisai Inc.

Type Press Release

Date Released April 06, 2016

May 9, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Apr 26, 2022

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody...

Apr 7, 2022

Eisai stands with people living with Alzheimer’s disease (AD), health care professionals and other members of our AD community. We respect that the Centers for Medicare and Medicaid Services...

Alerts - Release page
* Required Fields